Lu-177 DOTA-TATE therapy is a modern and innovative treatment method frequently used in patients with neuroendocrine tumors, especially when other treatment options such as surgery or chemotherapy are not suitable or effective.
Neuroendocrine tumors (NETs) are a rare type of cancer that can occur in various parts of the body, particularly in the intestines, pancreas, and lungs. These heterogeneous cancer types often exhibit an overexpression of somatostatin receptors (SSTR).
Theranostics is a novel and evolving approach in medicine. This methodology integrates imaging and treatment into a unified system, allowing simultaneous specific treatment and monitoring.
In cases of neuroendocrine tumors, where Ga-68 DOTA-TATE PET/CT enables highly sensitive and specific imaging of tumoral tissues, Lu-177 DOTA-TATE provides targeted and specific treatment for these tumoral tissues. This is considered a major advancement and an innovative method in theranostic applications.
Neuroendocrine tumors (NETs) are a rare type of cancer that can occur in various parts of the body, particularly in the intestines, pancreas, and lungs. These heterogeneous cancer types often exhibit an overexpression of somatostatin receptors (SSTR).
Theranostics is a novel and evolving approach in medicine. This methodology integrates imaging and treatment into a unified system, allowing simultaneous specific treatment and monitoring.
In cases of neuroendocrine tumors, where Ga-68 DOTA-TATE PET/CT enables highly sensitive and specific imaging of tumoral tissues, Lu-177 DOTA-TATE provides targeted and specific treatment for these tumoral tissues. This is considered a major advancement and an innovative method in theranostic applications.
DOTA-TATE therapy, also known as “targeted radionuclide therapy,” “peptide receptor radionuclide therapy (PRRT),” or “somatostatin receptor radioligand therapy,” involves the administration of labeled peptides via intravenous injection. Peptides bound to DOTA-TATE combine with Lutetium-177, delivering high doses of localized radiotherapy directly to the tumor.
The beta radiation emitted by Lutetium-177 generates free radicals in somatostatin receptor-positive cells and surrounding tissues, inducing cellular damage. This therapy aims to effectively target and treat neuroendocrine tumors by slowing or halting tumor growth and alleviating tumor-related symptoms.
This treatment is typically administered in four cycles, spaced 8 to 12 weeks apart. It offers an effective strategy for managing neuroendocrine tumors while improving the patient’s quality of life.
DOTA-TATE is an FDA-approved treatment for patients with neuroendocrine tumors (NETs). It is usually administered in four cycles at eight-week intervals. The therapy is preferred when surgery or chemotherapy options are either not suitable or ineffective.
Studies have shown that DOTA-TATE can extend life expectancy, improve overall quality of life, and alleviate symptoms in NET patients. Before considering this treatment, a Ga-68 DOTA-TATE PET/CT scan should be performed to determine the positivity of somatostatin receptors in the patient’s tumors and metastases.
Each patient requires an individualized treatment plan, and the process must be carefully monitored to ensure suitability for therapy.
It is important to remember that every patient is unique, and treatment plans should be tailored to the patient’s specific condition. Therefore, a thorough evaluation must be conducted before initiating DOTA-TATE therapy, guided by a qualified healthcare professional.
Radiation therapy for NET patients is an effective treatment method with fewer side effects compared to other cancer treatments.
Radiation therapy uses high-energy beams to target the tumor and damage the DNA of cancer cells, preventing their growth and proliferation.
Since the radiation used in this treatment may potentially affect the kidneys and bone marrow, regular blood tests are required after the procedure to monitor the patient’s condition.
The side effects of Lu-177 DOTA-TATE therapy can be classified into two categories:
The side effects of Lu-177 therapy are generally mild and temporary. However, more serious side effects may occur in some patients. Discussing potential side effects with your doctor before starting treatment is essential.
Due to the involvement of radiation, DOTA-TATE therapy is not suitable during pregnancy. Women of childbearing age must undergo a pregnancy test before starting treatment. Both men and women are advised to avoid pregnancy during and for at least six months after completing the treatment. Reliable contraceptive methods should be used during this period.
Patients undergoing Lu-177 DOTA-TATE therapy are regularly monitored to evaluate the effectiveness and safety of the treatment. Follow-ups assess symptoms, detect potential treatment-related effects, and monitor disease progression.
The follow-up plan is tailored to the patient’s individual needs. Typically, the first follow-up occurs 1-2 weeks after treatment to evaluate any immediate side effects. Subsequent follow-ups are generally conducted every 3-6 months to assess the therapy’s effectiveness and safety.
Patients undergoing Lu-177 DOTA-TATE therapy are regularly monitored to evaluate the effectiveness and safety of the treatment. Follow-ups assess symptoms, detect potential treatment-related effects, and monitor disease progression.
The follow-up plan is tailored to the patient’s individual needs. Typically, the first follow-up occurs 1-2 weeks after treatment to evaluate any immediate side effects. Subsequent follow-ups are generally conducted every 3-6 months to assess the therapy’s effectiveness and safety.
or inquiries about the cost, process, and insurance coverage by SGK, please contact us through our communication center. Detailed information about the application procedures and average costs can also be provided.
Expert professionals will provide detailed explanations about Lutetium-177 DOTA-TATE therapy.
You can send the necessary referral documents via email to ir@neolife.com.tr or contact us by phone at +90 549 523 69 23.
For more detailed information about Lutetium-177 DOTA-TATE, please click here.
